The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity, a study found.

Janssen has retained its rights to develop and commercialize B-cell targeting CD28 bispecific antibodies, including JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28). "Plamotamab is a Phase 2 ...

Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. This results in local T-cell ...

“CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.” Croatian Medical Journal: “Therapies for multiple sclerosis targeting B cells.” National Multiple ...